| Scientific Name |
Ciltacabtagene Autoleucel
|
|---|---|
| Brand Name |
CARVYKTI
|
| Risk |
1. CRS (including HLH) 2. Neurologic toxicities (including ICANS and other neurotoxicities) 3. Secondary malignancy of T-cell origin 4. Secondary malignancy of myeloid origin 5. Decrease in cell viability due to inappropriate handling or preparation of the product
|
| Educational Materials for Healthcare Professionals |
|
| Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals |
|
| Safety Communication for Healthcare Professionals |
|
| Educational Materials for Patients |
|